MedPath

The effect of protein hydrolysate supplementation to preserve muscle mass during immobilisation and enhance muscle regain during recovery

Completed
Conditions
healthy, young subjects
Registration Number
NL-OMON24953
Lead Sponsor
uritas
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

1) Male
2) Aged 18-35 y
3) BMI 18.5-30.0 kg/m2

Exclusion Criteria

1) (Family) history of thrombosis
2) (Family) history of Factor V Leiden, or other known thrombophilia (such as; protein C, protein S, antithrombin deficiency)
3) Lower limb, back or shoulder injuries (which may interfere with the use of crutches)
4) Allergies to milk protein
5) Lactose intolerance
6) Participation in structured resistance exercise program
7) All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g., arthritis, spasticity/rigidity, all neurological disorders and paralysis)
8) Any medications known to (or may) affect protein metabolism (i.e., corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications)
9) Diagnosed diabetes
10) Diagnosed metabolic, cardiovascular or intestinal disorders
11) A history of neuromuscular problems
12) Use of anti-coagulants
13) Use of protein and/or fish-oil supplements
14) Participation in a 2H2O study in the previous 6 months.
15) Smoking
16) Any recent hospital admission/ major surgery

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
skeletal muscle mass (quadriceps muscle cross sectional area (CSA))
Secondary Outcome Measures
NameTimeMethod
maximal leg muscle strength (1RM), whole-leg muscle CSA, type I and II muscle fibre size, muscle protein synthesis rates, and muscle signalling and gene transcription responses
© Copyright 2025. All Rights Reserved by MedPath